• Olivier joined Andera Partners in 2006.
  • Olivier holds a PhD in molecular microbiology from University of Munich (LMU). During his scientific work he focused on fundamental and applied sciences relating to molecular regulation mechanisms in antibiotic biosynthesis.
  • In 1998, Olivier joined Mercer Management Consulting in Munich to work on strategic business projects in the healthcare and other industries,  in Europe, the US, and Asia.
  • Attracted by the emerging biotechnology industry in continental Europe, Olivier joined 3i’s Munich-based Life Sciences practice in 2000. There, he was responsible for investing and managing Life Sciences portfolio companies in Germany, in both biotechnology and medical devices. In 2004, he moved to Paris and led the Life Sciences Venture Capital activities for 3i in France, were he accompanied several exits in the legacy portfolio and invested in new companies in France and in the US. During his tenure at 3i, Olivier became acquainted with the Life Sciences team of Andera, and decided to join them in 2006 to jointly build up the activity to one of the leading players in Europe.
  • Olivier currently serves on the board of  MMI Microsystems, T-Knife, Arvelle Therapeutics, Allecra Therapeutics, HighLife Medical, MedLumics, Tricares and JenaValve. He was also a board member of Corvidia, Sapiens, Endosense, Novexel and Supersonic Imagine up until their respective acquisitions by large pharmaceutical or medical device companies.

 

Investments of Olivier

08.2007 - andera Life Sciences In portfolio

JenaValve

Development of a non-invasive valve replacement technology

03.2017 - andera Life Sciences In portfolio

MedLumics

Next generation ablation catheter for the treatment of cardiac arrhythmias

04.2018 - andera Life Sciences In portfolio

Medical Micro Instruments

Robotic assisted microsurgery platform

12.2018 - andera Life Sciences In portfolio

Highlife Medical

Prosthetic mitral valve

12.2018 - andera Life Sciences In portfolio

T-Knife

Cell therapy for the treatment of cancers

04.2018 - andera Life Sciences Sold

Corvidia Therapeutics

Molécule pour le traitement de l’inflammation chez les patients insuffisants rénaux

02.2019 - andera Life Sciences Sold

Arvelle

Small molecule for the treatment of pharmacoresistant partial epilepsy

06.2018 - andera Life Sciences In portfolio

Tricares

Development of minimally invasive treatment of tricuspid regurgitation

06.2011 - andera Life Sciences Sold

Sapiens

Deep brain stimulation system for the treatment of Parkinson’s disease

08.2009 - andera Life Sciences Sold

Endosense

Force-sensing ablation catheters for the treatment of cardiac arrhythmias

10.2008 - andera Life Sciences Sold

SuperSonic Imagine

Ultrasound technology measuring tissue elasticity for cancer detection

10.2009 - andera Life Sciences In portfolio

Vivoryon

Development of innovative molecule drugs for the treatment of neurodegenerative diseases

04.2013 - andera Life Sciences In portfolio

Allecra

Development of novel treatments to combat multi drug-resistant bacterial infections